Table 2 |
|||
|
Baseline data for bone mineral density (BMD) and serum bone markers in patients with rheumatoid arthritis (RA) |
|||
|
BMD/serum bone markers |
Bisphosphonate group (n = 42) |
Bisphosphonate + statin group (n = 35) |
P-value Student's t-test |
|
|
|||
|
BMD, g/cm2 |
|||
|
Radius |
0.35 ± 0.08 (0.12, 0.54) |
0.33 ± 0.13 (0.11, 0.63) |
0.547 |
|
Lumbar spine |
0.82 ± 0.18 (0.50, 1.32) |
0.82 ± 0.180 (0.51, 1.40) |
0.974 |
|
Femoral neck |
0.64 ± 0.09 (0.39, 0.81) |
0.60 ± 0.13 (0.33, 0.79) |
0.096 |
|
NTX, nmol BCE/l |
16.3 ± 5.4 (9.7, 35.6) |
15.8 ± 4.2 (9.3, 27.9) |
0.690 |
|
TRACP-5b, μU/dl |
357 ± 1287(131, 628) |
350 ± 102 (174, 652) |
0.820 |
|
PICP, ng/ml |
612 ± 218 (384, 1490) |
562 ± 205 (289, 1340) |
0.315 |
|
RANKL, pmol/l |
0.27 ± 0.36 (0.13, 1.92) |
0.16 ± 0.11 (0.13, 0.63) |
0.093 |
|
|
|||
|
Results are presented as mean ± SD (range). NTX, N-terminal telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphate-5b; PICP, C-terminal propeptide of type I procollagen; RANKL, receptor activator of NF-κB ligand. P-values are for comparisons between the two treatment groups. |
|||
|
Nagashima et al. Arthritis Research & Therapy 2012 14:R224 doi:10.1186/ar4063 |
|||
